Gilead Sciences Inc. announced that Roy D. Baynes, MD, PhD, will join the company as senior vice president, Oncology Therapeutics.

In this position, Baynes will report to Norbert W. Bischofberger, PhD, chief scientific officer, executive vice president, research and development, and will have responsibility for Gilead’s programs in oncology. Baynes will also join Gilead’s Executive Committee.

Baynes joins Gilead from Amgen, where he served as vice president of Global Development and Therapeutic Area, and head of Hematology Oncology.

Release Date: Jan. 18, 2012-
Source: Gilead Sciences Inc.